XERS Profile
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies across endocrinology, neurology, and gastroenterology. Leveraging its proprietary formulation technologies, the company aims to address critical medical needs in these fields by offering solutions that improve patient outcomes and enhance therapeutic efficacy.
The company's flagship product, Gvoke, is a ready-to-use liquid glucagon designed for the rapid treatment of severe hypoglycemia, a potentially life-threatening condition often associated with diabetes management. Another significant offering, Keveyis, is a specialized therapy targeting hyperkalemic, hypokalemic, and related variants of primary periodic paralysis, providing relief for patients suffering from these rare neuromuscular disorders. Additionally, Xeris markets Recorlev, a cortisol synthesis inhibitor used in the treatment of endogenous hypercortisolemia associated with Cushing's syndrome, a condition characterized by excessive cortisol production.
Xeris Biopharma is also advancing a robust pipeline of development programs aimed at expanding the indications and applications of its existing products. The company's proprietary formulation platforms, XeriSol and XeriJect, underpin its strategy to innovate and bring new therapies to market. XeriSol offers an advanced, stable formulation technology for injectable medications, while XeriJect provides a novel approach to delivering complex biologics and small molecules, potentially transforming how these therapies are administered.
Incorporated in 2005 and headquartered in Chicago, Illinois, Xeris Biopharma Holdings, Inc. continues to build on its expertise and technology platforms to address unmet medical needs. The company's commitment to innovation and patient care positions it as a leader in the biopharmaceutical industry, striving to make significant impacts through its novel therapeutic solutions.
|
